Damora Therapeutics, Inc.
Damora Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies, primarily focused on the discovery and development of product candidates DMR-001, DMR-002, and DMR-003.
Business. Damora Therapeutics, Inc. (DMRA) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Damora Therapeutics, Inc. (DMRA) has seen a wave of new institutional interest, with multiple investors initiating notable positions in the company’s stock. This activity marks the first analysis for the ticker, meaning there is no prior baseline for comparison, but the influx of new holders signals emerging attention from the investment community. The most significant new position was established by investor ID 491, who acquired 1,058,000 shares valued at approximately $27.4 million as of March 31, 2026. This single holding represents a weight of roughly 0.51% in the investor’s portfolio, making it the largest new stake among the reported changes. Other notable additions include investor ID 471, who took a position of 241,126 shares worth about $6.25 million, and investor ID 467, who acquired 183,922 shares valued at approximately $4.76 million. Additional new holders include investor ID 499 with 160,415 shares ($4.15 million), investor ID 486 with 96,777 shares ($2.51 million), investor ID 481 with 12,500 shares ($0.32 million), and investor ID 465 with 18,247 shares ($0.42 million) as of December 31, 2025. These new stakes contribute to Damora’s current shareholder base, which includes 12 top holders. The company currently has no listed officers, analysts, or index memberships, suggesting that this recent accumulation of shares by specific investors may be a primary driver of visibility for the stock at this stage.
Signals & dispatch
Composite-score breakdown
Synthesis
Damora Therapeutics, Inc. (DMRA) is a pharmaceutical company operating within the Healthcare sector. The firm is headquartered in the United States and is primarily listed on the Nasdaq stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Damora Therapeutics maintains a robust liquidity position with $532.9 million in cash and equivalents against total liabilities of $23.8 million, resulting in a current ratio of 22.48 and a debt-to-equity ratio of 0.0. The company holds a market capitalization of $1.13 billion and trades at a price-to-book ratio of 2.21. Despite strong liquidity, the firm reported an operating cash flow burn of $20.6 million in Q1 2026, driven by a net loss of $27.8 million. The balance sheet reflects total assets of $535.4 million and total equity of $511.6 million, indicating a capital-intensive pre-revenue stage with no debt obligations.
Profitability metrics remain negative, consistent with early-stage biopharma profiles. Return on equity stands at -5.43% and return on assets at -5.19%. The company reports no revenue, resulting in an undefined EV/EBITDA multiple (listed as -19.05 due to negative EBITDA). These returns reflect the significant investment in research and development required to advance its pipeline, with no near-term path to positive earnings.
The company’s operations are concentrated in its core pharmaceutical development activities, with no disclosed segment revenue mix. Geographic exposure is primarily domestic, with subsidiaries including Galecto Biotech AB in Sweden and Galecto Biotech ApS in Denmark, supporting its R&D infrastructure. The lack of revenue concentration risk is offset by the total dependence on successful clinical outcomes for future value creation.
Growth trajectory is defined by capital deployment rather than top-line expansion. Q1 2026 net loss of $27.8 million represents a significant increase from the $2.5 million net loss in Q1 2025, reflecting accelerated R&D spend and stock-based compensation of $3.1 million. The company raised $295.5 million in net proceeds from a public offering in February 2026, bolstering its cash runway. Shares outstanding increased to 60.3 million basic shares, up from 1.3 million in the prior year, due to the conversion of preferred stock and new issuances.
Risk factors include medium dilution risk, driven by an active ATM offering program and recent equity issuances. Filings reference going-concern or substantial-doubt language, although current liquidity mitigates immediate solvency concerns. The company faces standard biopharma risks related to clinical trial success, regulatory approval, and intellectual property protection. The presence of warrant obligations and convertible preferred stock adds complexity to the capital structure.
Recent events include the filing of an 8-K on February 10, 2026, detailing a shelf registration statement and public offering. The company also disclosed the conversion of Series C non-voting convertible preferred stock into common stock. Forward-looking statements highlight the strategic focus on DMR-001, DMR-002, and DMR-003, with risks related to clinical execution, regulatory timelines, and market acceptance. The company continues to expand its equity incentive plans, including the 2026 Stock Option and Grant Plan.
Damora Therapeutics, Inc. (DMRA) has seen a wave of new institutional interest, with multiple investors initiating notable positions in the company’s stock. This activity marks the first analysis for the ticker, meaning there is no prior baseline for comparison, but the influx of new holders signals emerging attention from the investment community. The most significant new position was established by investor ID 491, who acquired 1,058,000 shares valued at approximately $27.4 million as of March 31, 2026. This single holding represents a weight of roughly 0.51% in the investor’s portfolio, making it the largest new stake among the reported changes. Other notable additions include investor ID 471, who took a position of 241,126 shares worth about $6.25 million, and investor ID 467, who acquired 183,922 shares valued at approximately $4.76 million. Additional new holders include investor ID 499 with 160,415 shares ($4.15 million), investor ID 486 with 96,777 shares ($2.51 million), investor ID 481 with 12,500 shares ($0.32 million), and investor ID 465 with 18,247 shares ($0.42 million) as of December 31, 2025. These new stakes contribute to Damora’s current shareholder base, which includes 12 top holders. The company currently has no listed officers, analysts, or index memberships, suggesting that this recent accumulation of shares by specific investors may be a primary driver of visibility for the stock at this stage.
- Strong liquidity with $532.9M in cash and zero debt, providing a multi-year runway for R&D.
- Significant dilution from recent $295.5M public offering and preferred stock conversions, increasing shares outstanding to 60.3M.
- Accelerating burn rate with Q1 2026 net loss of $27.8M, up from $2.5M in Q1 2025, driven by R&D and stock-based compensation.
- No revenue generation; value is entirely dependent on the clinical success of DMR-001, DMR-002, and DMR-003.
- Active ATM offering program and equity incentive plans indicate ongoing capital needs and potential future dilution.
- Going-concern language in filings highlights the inherent risks of pre-revenue biopharma operations.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Operating income -$30.8M.
- ▍Operating income -$30.8M
Operating income -$9.2M.
- ▍Operating income -$9.2M
Operating income -$6.0M.
- ▍Operating income -$6.0M
Operating income -$210.9M.
- ▍Operating income -$210.9M
Operating income -$22.3M.
- ▍Operating income -$22.3M
Operating income -$22.3M.
- ▍Operating income -$22.3M
Operating income -$39.9M.
- ▍Operating income -$39.9M
Operating income -$39.9M.
- ▍Operating income -$39.9M
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Filings reference going-concern or substantial-doubt language.
- Source documents mention dilution or offering risk.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Derivative transactions
- General Counsel · Restricted Stock Units → Common StockDisposed 680exercise · 2026-07-03
- Director, See Remarks · Stock Option (right to buy) → Common StockAcquired 1 500 000 @ $25,50grant · 2026-03-30
- Director · Stock Option (right to buy) → Common StockAcquired 37 313 @ $23,05grant · 2026-03-23
- Director · Stock Option (right to buy) → Common StockAcquired 37 313 @ $23,05grant · 2026-03-23
- General Counsel · Stock Option (right to buy) → Common StockAcquired 250 000 @ $23,05grant · 2026-03-23
- Director, 10% owner · Stock Option (right to buy) → Common StockAcquired 37 313 @ $23,05grant · 2026-03-23
- Director · Stock Option (right to buy) → Common StockAcquired 37 313 @ $23,05grant · 2026-03-23
- Director · Stock Option (right to buy) → Common StockAcquired 37 313 @ $23,05grant · 2026-03-23
- Director · Series C Preferred Stock → Common StockDisposed 129 000exercise · 2026-02-09
- Director, 10% owner · Series C Preferred Stock → Common StockDisposed 2 904 000exercise · 2026-02-09
- Director, 10% owner · Series C Preferred Stock → Common StockDisposed 5 809 000exercise · 2026-02-09
- Chief Operating Officer · Stock Option (right to buy) → Common StockAcquired 444 209 @ $21,82grant · 2026-01-05
- Chief Medical Officer · Stock Option (right to buy) → Common StockAcquired 528 603 @ $21,82grant · 2026-01-05
- General Counsel · Restricted Stock Units → Common StockDisposed 680exercise · 2026-01-02
- Chief Financial Officer · Restricted Stock Units → Common StockDisposed 374exercise · 2026-01-02
- Director, Chief Executive Officer · Restricted Stock Units → Common StockDisposed 1 360exercise · 2026-01-02
Actions
Ask Handelsavisen
- Market data
- Regulatory filings
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Return On Equitynet_income / total_equity
- Enterprise Valuemarket_cap - net_cash
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Damora Therapeutics, Inc. company facts · 2026-07-21
- Damora Therapeutics, Inc. 10-Q 2026-05-12 · 2026-07-21
- Damora Therapeutics, Inc. 10-K 2026-03-19 · 2026-07-21
- Damora Therapeutics, Inc. 10-Q 2025-11-06 · 2026-07-21
- Damora Therapeutics, Inc. 10-Q 2025-08-05 · 2026-07-21
- 8-K (sec_8k_material) on DMRA · 2026-07-21
- Damora Therapeutics, Inc. HA canonical relationships · 2026-07-21
Ownership & reference
Top holders
- Institutional Investor · as of 2026-03-310,01 %$234M
- Investment Managers · as of 2026-03-310,01 %$27M
- Investment Managers · as of 2026-03-310,00 %$4M
- Institutional Investor · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$6M
- Investment Managers · as of 2026-03-310,00 %$2M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$3M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2025-12-310,00 %$0M
- Investment Managers · as of 2024-06-300,00 %$0M
Insider activity
- General Counsel · Common StockSold 245 @ $29,98$7K · 2026-07-06
- General Counsel · Common StockOther 680 · 2026-07-03
- Director, See Remarks · Common StockOther 500 000 · 2026-03-30
- Director, 10% owner · Common StockOther 2 904 000 · 2026-02-09
- Director · Common StockOther 129 000 · 2026-02-09
- Director, 10% owner · Common StockOther 5 809 000 · 2026-02-09
- Chief Medical Officer · Common StockOther 264 629 · 2026-01-05
- Chief Operating Officer · Common StockOther 190 376 · 2026-01-05
- Director, Chief Executive Officer · Common StockSold 700 @ $21,38$15K · 2026-01-02
- General Counsel · Common StockOther 680 · 2026-01-02
- Chief Financial Officer · Common StockOther 374 · 2026-01-02
- Chief Financial Officer · Common StockSold 135 @ $21,41$3K · 2026-01-02
- General Counsel · Common StockSold 255 @ $21,38$5K · 2026-01-02
- Director, Chief Executive Officer · Common StockOther 1 360 · 2026-01-02
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Operating income (annual): USD -210.87MUnknown
- Current assets (annual): USD 260.42MUnknown
- Net income (annual): USD -209.84MUnknown
- Cash & equivalents (annual): USD 257.62MUnknown
- Shareholders' equity (annual): USD 240.38MUnknown
- Total assets (annual): USD 260.53MUnknown
- Shares outstanding (annual): 1.6MUnknown
- Current liabilities (annual): USD 20.07MUnknown
- Total liabilities (annual): USD 20.15MUnknown
- Operating cash flow (annual): USD -6.73MUnknown
- Total operating expenses (annual): USD 210.87MUnknown
- EPS (basic) (annual): USD-PER-SHARES 4Unknown
- R&D expense (annual): USD 26.88MUnknown
- EPS (diluted) (annual): USD-PER-SHARES 4Unknown
- Pre-tax income (annual): USD -209.79MUnknown
- Cash & equivalents (annual): USD 14.18MUnknown
- R&D expense (annual): USD 6.4MUnknown
- Shareholders' equity (annual): USD 15.83MUnknown
- Shares outstanding (annual): 1.32MUnknown
- EPS (diluted) (annual): USD-PER-SHARES -19Unknown
- Total assets (annual): USD 17.13MUnknown
- Total liabilities (annual): USD 1.3MUnknown
- Current liabilities (annual): USD 1.2MUnknown
- Total operating expenses (annual): USD 22.26MUnknown